<PAGE> 1
FORM 10-C
SECURITIES AND EXCHANGES COMMISSION
WASHINGTON, DC 20549
REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ INTER-DEALER QUOTATION SYSTEM
FILED PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 AND
RULES 13a-17 AND 15d-17 THEREUNDER
CAMBRIDGE NEUROSCIENCE, INC.
(Exact Name of Issuer as Specified in Charter)
ONE KENDALL SQUARE, BUILDING 700, CAMBRIDGE, MA 02139
(Address of Principal Executive Offices)
(617) 225-0600
(Issuer's Telephone Number, Including Area Code)
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of five percent or more in the number
of shares outstanding:
1. Title of security COMMON STOCK
2. Number of shares outstanding before the change 13,573,411
3. Number of shares outstanding after the change 14,811,035
4. Effective date of change SEPTEMBER 6, 1996
5. Method of change
Specify method (such as merger, acquisition, exchange, distribution, stock
split, reverse split, acquisition of stock for treasury, etc.)
Give brief description of transaction SALE OF 1,237,624 SHARES OF COMMON
STOCK AT $8.08 PER SHARE.
II. CHANGE IN NAME OF ISSUER
1. Name prior to change N/A
2. Name after change N/A
3. Effective date of charter amendment changing name N/A
4. Date of shareholder approval of change, if required N/A
Date September 6, 1996 /s/ Harry W. Wilcox III
------------------------- --------------------------------
Senior V.P. Finance and Business
Development
